OR WAIT null SECS
Under the terms of the contract, Meissner will expand its Camarillo, Calif., manufacturing site by adding additional cleanroom manufacturing space, executing advanced inventory management systems, and adding support areas to supplement capacity.
Meissner Filtration Products, an advanced microfiltration products and single-use systems manufacturer, announced on April 30, 2021 that it was awarded a $13.4 million contract from the US Biomedical Advanced Research and Development Authority (BARDA) to expand production capacity for products necessary for the manufacturing of COVID-19 vaccines and therapeutics.
Under the terms of the contract, Meissner will expand its Camarillo, Calif., manufacturing site by adding additional cleanroom manufacturing space and support areas, as well as using inventory management systems, Meissner said in a company press release.
“Meissner has experienced substantial demand for our products associated with federally funded vaccine and therapeutics manufacturing efforts,” said Christopher Meissner, CEO of Meissner, in the press release. “It has been incredibly fulfilling for our organization to be able to make a direct impact fighting this pandemic, and this contract serves to amplify and accelerate those efforts.”
“While we have seen increased demand on the basis of COVID-19 vaccines and therapeutics, our products are also a key piece in the development and manufacture of other lifesaving medicines, so it’s critical that we able to support all of our customers through this period and in the future,” added Max Blomberg, executive director of Operations, Meissner, in the press release. “This expansion, which will provide a substantial capacity augmentation for our Camarillo campus, is just the latest in our continuing work to ensure we scale with our clients’ needs.”